SEC Comment Letter for Oncocyte Corp (OCX) (CIK 0001642380) (IMDX) — Jun 11, 2019

Oncocyte Corp (OCX) (CIK 0001642380)
Date: June 11, 2019 · CIK: 0001642380 · Accession: 0000000000-19-009713

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-231980

Date

June 11, 2019

Author

Not clearly detected

Form

UPLOAD

Company

Oncocyte Corp (OCX) (CIK 0001642380)

Letter

June 11, 2019 William Annett Chief Executive Officer OncoCyte Corporation 1010 Atlantic Avenue, Suite 102 Alameda, CA 94501 Re:OncoCyte Corporation Registration Statement on Form S-3 Filed June 6, 2019 File No. 333-231980 Dear Mr. Annett: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Donald Field at 202-551-3680 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

June 11, 2019
William Annett
Chief Executive Officer
OncoCyte Corporation
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501
Re:OncoCyte Corporation
Registration Statement on Form S-3
Filed June 6, 2019
File No. 333-231980
Dear Mr. Annett:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Donald Field at 202-551-3680 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io